BeiGene (FRA:49BA) Additional Paid-In Capital : €10,636 Mil(As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene Additional Paid-In Capital?

BeiGene's quarterly additional paid-in capital declined from Jun. 2023 (€10,847 Mil) to Sep. 2023 (€10,778 Mil) but then stayed the same from Sep. 2023 (€10,778 Mil) to Dec. 2023 (€10,636 Mil).

BeiGene's annual additional paid-in capital increased from Dec. 2021 (€9,904 Mil) to Dec. 2022 (€10,895 Mil) but then declined from Dec. 2022 (€10,895 Mil) to Dec. 2023 (€10,636 Mil).

BeiGene Additional Paid-In Capital Historical Data

The historical data trend for BeiGene's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Additional Paid-In Capital Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

2,633.37

6,095.07

9,904.04

10,894.68

10,636.00

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															10,894.68	10,876.39	10,847.11	10,777.87	10,636.00

BeiGene Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

BeiGene Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BeiGene's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines